RTP Mobile Logo
Gastrointestinal Cancer Update, Issue 2, 2015
Released March 2016

Featuring interviews with Drs Scott Kopetz and David P Ryan. (Audio Content)

CE Disclosures and Faculty Information

    Colorectal cancer (CRC) is a common and potentially lethal type of cancer, and its clinical management is constantly evolving. Although “non-CRC” gastrointestinal (GI) tumors are less frequently encountered individually, the cancer-related deaths in that subcategory surpass those attributed to CRC. Published results from ongoing trials continuously lead to the emergence of novel biomarkers and new therapeutic targets and regimens, thereby altering existing management algorithms. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well informed of these advances. To bridge the gap between research and patient care, Gastrointestinal Cancer Update uses one-on-one discussion with leading GI oncology investigators. By providing access to the latest scientific developments and the perspectives of experts in the field, this CME activity assists medical oncologists with the formulation of up-to-date management strategies.


    • Apply existing and emerging data to the best-practice management of diverse GI cancers.
    • Communicate the benefits and risks of approved anti-VEGF, anti-EGFR and other targeted biologic therapies to patients with metastatic CRC (mCRC), and develop an evidence-based algorithm to sequence available options based on disease- and patient-specific characteristics.
    • Appraise the rationale for and clinical data with investigational anti-PD-1 and/or anti-PD-L1 antibodies in patients with CRC or gastric cancer.
    • Consider age, performance status and other clinical factors in the selection of systemic therapy for patients with metastatic pancreatic adenocarcinoma.
    • Coordinate comprehensive biomarker analysis for patients diagnosed with advanced CRC, and use this information to guide evidence-based care for these patients.
    • Develop an evidence-based plan of care for the treatment of peritoneal carcinomatosis of CRC origin.
    • Assess available data with currently approved and investigational agents with documented activity in gastroesphageal cancer, and develop a clinical algorithm for optimal patient care including the option of participating in clinical research.
    • Counsel appropriately selected patients with GI cancer about participation in ongoing clinical trials.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue


    CME credit is no longer available for this issue

    This CME activity contains an audio component.

    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr KopetzConsulting Agreements: Agendia, Amgen Inc, Array BioPharma Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Genentech BioOncology, GlaxoSmithKline, Merrimack Pharmaceuticals Inc, Roche Laboratories Inc, Sanofi, Sysmex Inostics, Taiho Oncology Inc; Contracted Research: Agendia, Amgen Inc, Biocartis, Genentech BioOncology, GlaxoSmithKline, Guardant Health Inc, Roche Laboratories Inc, Sanofi, Sysmex Inostics. Dr RyanAdvisory Committee: Pfizer Inc.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Boston Biomedical Pharma Inc, Celgene Corporation, Genentech BioOncology, Novartis Pharmaceuticals Corporation and Taiho Oncology Inc.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: March 2016
    Expiration date: March 2017

Acknowledge and close

Listen to audio:
Gastrointestinal Cancer Update, Issue 2, 2015
Released March 2016

Featuring interviews with Drs Scott Kopetz and David P Ryan. (Audio Content)

Read print: